HIF-2α regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth

Genes and Development

Volumn 20, Issue 5, 2006, Pages 557-570

  Covello, Kelly L ^a   Kehler, James ^c   Yu, Hongwei ^b   Gordan, John D ^b   Arsham, Andrew M ^b,d   Hu, Cheng Jun ^b   Labosky, Patricia A ^a   Simon, M Celeste ^a,b   Keith, Brian ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cancer; HIF; HIF 2 ; Hypoxia; Oct 4; Stem cells; TGF ; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OCTAMER TRANSCRIPTION FACTOR 4; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HYPOXIA INDUCIBLE FACTOR 2, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR 2, ALPHA SUBUNIT; MESSENGER RNA; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HOMOZYGOSITY; HYPOXIA; MOUSE; NONHUMAN; PRIMORDIAL GERM CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; TUMOR GROWTH; TUMOR PROMOTION; ALLELE; ANIMAL; BIOLOGICAL MODEL; CELL HYPOXIA; CELL TRANSFORMATION; COMPARATIVE STUDY; CYTOLOGY; DOWN REGULATION; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PREGNANCY; STEM CELL; TERATOMA;

ANIMALIA;

ALLELES; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; EMBRYONIC DEVELOPMENT; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MODELS, GENETIC; OCTAMER TRANSCRIPTION FACTOR-3; PREGNANCY; RNA, MESSENGER; STEM CELLS; TERATOMA; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644747418     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1399906     Document Type: Article

References (62)

1. Acker, T., Diez-Juan, A., Aragones, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D., Moreno-Murciano, M.P., Herbert, J.M., Burger, A., et al. 2005. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8: 131-141.
2. Adelman, D.M., Maltepe, E., and Simon, M.C. 1999. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes & Dev. 13: 2478-2483.
3. Boiani, M., Eckardt, S., Scholer, H.R., and McLaughlin, K.J. 2002. Oct4 distribution and level in mouse clones: Consequences for pluripotency. Genes & Dev. 16: 1209-1219.
4. Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., Guenther, M.G., Kumar, R.M., Murray, H.L., Jenner, R.G., et al. 2005. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956.
5. Cheng, L., Thomas, A., Roth, L.M., Zheng, W., Michael, H., and Karim, F.W. 2004. OCT4: A novel biomarker for dysgerminoma of the ovary. Am. J. Surg. Pathol. 28: 1341-1346.
6. Compernolle, V., Brusselmans, K., Acker, T., Hoet, P., Tjwa, M., Beck, H., Plaisance, S., Dor, Y., Keshet, E., Lupu, F., et al. 2002. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8: 702-710.
7. Compernolle, V., Brusselmans, K., Franco, D., Moorman, A., Dewerchin, M., Collen, D., and Carmeliet, P. 2003. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1α. Cardiovasc. Res. 60: 569-579.
8. Covello, K.L., Simon, M.C., and Keith, B. 2005. Targeted replacement of hypoxia-inducible factor-1α by a hypoxia-inducible factor-2α knock-in allele promotes tumor growth. Cancer Res. 65: 2277-2286.
9. Danet, G.H., Pan, Y., Luongo, J.L., Bonnet, D.A., and Simon, M.C. 2003. Expansion of human SCID-repopulating cells under hypoxic conditions. J. Clin. Invest. 112: 126-135.
10. Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., and Fujii-Kuriyama, Y. 1997. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Nat. Acad. Sci. 94: 4273-4278.
11. 2 tensions and the prevention of differentiation of hES cells. Proc. Nat. Acad. Sci. 102: 4783-4788.
12. Favier, J., Kempf, H., Corvol, P., and Gasc, J.M. 2001. Coexpression of endothelial PAS protein 1 with essential angiogenic factors suggests its involvement in human vascular development. Dev. Dyn. 222: 377-388.
13. Feldman, B., Poueymirou, W., Papaioannou, V.E., DeChiara, T.M., and Goldfarb, M. 1995. Requirement of FGF-4 for postimplantation mouse development. Science 267: 246-249.
14. Flamme, I., Frohlich, T., von Reutern, M., Kappel, A., Damert, A., and Risau, W. 1997. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels. Mech. Dev. 63: 51-60.
15. Giatromanolaki, A., Koukourakis, M.I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K.C., and Harris, A.L. 2001. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85: 881-890.
16. Gidekel, S., Pizov, G., Bergman, Y., and Pikarsky, E. 2003. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4: 361-370.
17. -/- renal cell carcinoma cells. J. Biol. Chem. 278: 44966-44974.
18. Harvey, A.J., Kind, K.L., Pantaleon, M., Armstrong, D.T., and Thompson, J.G. 2004. Oxygen-regulated gene expression in bovine blastocysts. Biol. Reprod. 71: 1108-1119.
19. Hochedlinger, K., Yamada, Y., Beard, C., and Jaenisch, R. 2005. Ectopic expression of oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121: 465-477.
20. Hu, C.J., Wang, L.Y., Chodosh, L.A., Keith, B., and Simon, M.C. 2003. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol. 23: 9361-9374.
21. 2 homeostasis by hypoxia-inducible factor 1α. Genes & Dev. 12: 149-162.
22. 2-regulated prolyl hydroxylation. Science 292: 468-472.
23. Jiang, Y., Jahagirdar, B.N., Reinhardt, R.L., Schwartz, R.E., Keene, C.D., Ortiz-Gonzalez, X.R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. 2002. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418: 41-49.
24. Jogi, A., Ora, I., Nilsson, H., Lindeheim, A., Makino, Y., Poellinger, L., Axelson, H., and Pahlman, S. 2002. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc. Nat. Acad. Sci. 99: 7021-7026.
25. Kehler, J., Tolkunova, E., Koschorz, B., Pesce, M., Gentile, L., Boiani, M., Lomeli, H., Nagy, A., McLaughlin, K.J., Scholer, H.R., et al. 2004. Oct4 is required for primordial germ cell survival. EMBO Rep. 5: 1078-1083.
26. Keller, G., Kennedy, M., Papayannopoulou, T., and Wiles, M.V. 1993. Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol. Cell. Biol. 13: 473-486.
27. Khatua, S., Peterson, K.M., Brown, K.M., Lawlor, C., Santi, M.R., LaFleur, B., Dressman, D., Stephan, D.A., and MacDonald, T.J. 2003. Overexpression of the EGFR/FKBP12/ HIF-2α pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 63: 1865-1870.
28. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., and Kaelin Jr., W.G. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246.
29. Kondo, K., Kim, W.Y., Lechpammer, M., and Kaelin Jr., W.G. 2003. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1: E83.
30. Letting, D.L., Rakowski, C., Weiss, M.J., and Blobel, G.A. 2003. Formation of a tissue-specific histone acetylation pattern by the hematopoietic transcription factor GATA-1. Mol. Cell. Biol. 23: 1334-1340.
31. Maranchie, J.K., Vasselli, J.R., Riss, J., Bonifacino, J.S., Linehan, W.M., and Klausner, R.D. 2002. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255.
32. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
33. Miquerol, L., Langille, B.L., and Nagy, A. 2000. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 18: 3941-3946.
34. Monk, M. and Holding, C. 2001. Human embryonic genes re-expressed in cancer cells. Oncogene 20: 8085-8091.
35. Morrison, S.J., Csete, M., Groves, A.K., Melega, W., Wold, B., and Anderson, D.J. 2000. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. J. Neurosci. 20: 7370-7376.
36. Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Scholer, H., and Smith, A. 1998. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95: 379-391.
37. Niwa, H., Miyazaki, J., and Smith, A.G. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat. Genet. 24: 372-376.
38. Nordhoff, V., Hubner, K., Bauer, A., Orlova, I., Malapetsa, A., and Scholer, H.R. 2001. Comparative analysis of human, bovine, and murine Oct-4 upstream promoter sequences. Mamm. Genome 12: 309-317.
39. Pugh, C.W., Tan, C.C., Jones, R.W., and Ratcliffe, P.J. 1991. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc. Nat. Acad. Sci. 88: 10553-10557.
40. Ramirez-Bergeron, D.L., Runge, A., Dahl, K.D., Fehling, H.J., Keller, G., and Simon, M.C. 2004. Hypoxia affects mesoderm and enhances hemangioblast specification during early development. Development 131: 4623-4634.
41. Ramos-Mejia, V., Escalante-Alcalde, D., Kunath, T., Ramirez, L., Gertsenstein, M., Nagy, A., and Lomeli, H. 2005. Phenotypic analyses of mouse embryos with ubiquitous expression of Oct4: Effects on mid-hindbrain patterning and gene expression. Dev. Dyn. 232: 180-190.
42. Raval, R.R., Lau, K.W., Tran, M.G., Sowter, H.M., Mandriota, S.J., Li, J.L., Pugh, C.W., Maxwell, P.H., Harris, A.L., and Ratcliffe, P.J. 2005. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25: 5675-5686.
43. Ryan, H.E., Lo, J., and Johnson, R.S. 1998. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17: 3005-3015.
44. Saitou, M., Barton, S.C., and Surani, M.A. 2002. A molecular programme for the specification of germ cell fate in mice. Nature 418: 293-300.
45. Scholer, H.R., Dressler, G.R., Balling, R., Rohdewohld, H., and Gruss, P. 1990a. Oct-4: A germline-specific transcription factor mapping to the mouse t-complex. EMBO J. 9: 2185-2195.
46. Scholer, H.R., Ruppert, S., Suzuki, N., Chowdhury, K., and Gruss, P. 1990b. New type of POU domain in germ line-specific protein Oct-4. Nature 344: 435-439.
47. Scortegagna, M., Morris, M.A., Oktay, Y., Bennett, M., and Garcia, J.A. 2003. The HIF family member EPAS1/HIF-2α is required for normal hematopoiesis in mice. Blood 102: 1634-1640.
48. Scortegagna, M., Ding, K., Zhang, Q., Oktay, Y., Bennett, M.J., Bennett, M., Shelton, J.M., Richardson, J.A., Moe, O., and Garcia, J.A. 2005. HIF-2α regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105: 3133-3140.
49. Semenza, G.L. 2000. HIF-1 and human disease: One highly involved factor. Genes & Dev. 14: 1983-1991.
50. Shimozaki, K., Nakashima, K., Niwa, H., and Taga, T. 2003. Involvement of Oct3/4 in the enhancement of neuronal differentiation of ES cells in neurogenesis-inducing cultures. Development 130: 2505-2512.
51. Spradling, A., Drummond-Barbosa, D., and Kai, T. 2001. Stem cells find their niche. Nature 414: 98-104.
52. Studer, L., Csete, M., Lee, S.H., Kabbani, N., Walikonis, J., Wold, B., and McKay, R. 2000. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J. Neurosci. 20: 7377-7383.
53. Tai, M.H., Chang, C.C., Olson, L.K., and Trosko, J.E. 2005. Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495-502.
54. Tian, H., McKnight, S.L., and Russell, D.W. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes & Dev. 11: 72-82.
55. Velkey, J.M. and O'Shea, K.S. 2003. Oct4 RNA interference induces trophectoderm differentiation in mouse embryonic stem cells. Genesis 37: 18-24.
56. Wang, V., Davis, D.A., Haque, M., Huang, L.E., and Yarchoan, R. 2005. Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells. Cancer Res. 65: 3299-3306.
57. Wenger, R.H. and Gassmann, M. 1997. Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. 378: 609-616.
58. Wiesener, M., Turley, H., Allen, W., William, C., Eckardt, K., Talks, K., Wood, S., Gatter, K., Harris, A., Pugh, C., et al. 1998. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1α. Blood 92: 2260-2268.
59. Wiesener, M.S., Jurgensen, J.S., Rosenberger, C., Scholze, C.K., Horstrup, J.H., Warnecke, C., Mandriota, S., Bechmann, I., Frei, U.A., Pugh, C.W., et al. 2003. Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J. 17: 271-273.
60. Wilkinson, D. 1992. In situ hybridization: A practical approach. Oxford University Press, London.
61. Wykoff, C.C., Sotiriou, C., Cockman, M.E., Ratcliffe, P.J., Maxwell, P., Liu, E., and Harris, A.L. 2004. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br. J. Cancer 90: 1235-1243.
62. Yeom, Y.I., Fuhrmann, G., Ovitt, C.E., Brehm, A., Ohbo, K., Gross, M., Hubner, K., and Scholer, H.R. 1996. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development 122: 881-894.